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The current Kidney Disease Outcomes Quality Initiative
(KDOQI) staging system of chronic kidney disease (CKD) is
simple but too rigid to accommodate variations in renal
function observed in the general population. The formula
most commonly used to estimate renal function is not
validated in subjects without a priori evidence of renal
disease. Their combined use results in inappropriate
diagnosis of CKD and improbable estimates of prevalence
rates. Although this initiative has raised the profile of kidney
disease, the exaggeration of the scope of the problem could
distract nephrologists from their specialist role. The
nephrology community needs a revised staging system for
CKD that allows accurate, effective, and timely
communication with patients, primary care doctors, public
health physicians, and policy makers. Its single most
important function will be to identify those patients who will
benefit from targeted screening and effective and safe
interventions. We offer for discussion a modified definition
and staging system of CKD based on the presence of
unequivocal, irreversible structural kidney disease, the
presence or degree of impairment of kidney function, and
the consequences thereof.
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In the past, the work of clinical nephrologists was largely
centered on the care of patients with ‘end stage’ chronic renal
failure and life-threatening acute kidney injury. Attention to
those patients with untreatable diseases en route to ‘end
stage’ chronic renal failure was perfunctory until it was
shown that progression could be slowed and complications of
renal insufficiency mitigated. Chronic kidney disease (CKD)
now receives appropriate attention in the expectation that
early diagnosis will allow implementation of measures to
delay the onset of, and reduce the incidence of ‘end stage’
chronic renal failure, and prevent presentation with advanced
uremia at the eleventh hour. Treatment of complications and
emphasis on the mitigation of cardiovascular risk factors
should reduce the morbidity and mortality of this chronic life
damaging and shortening illness.
To design a strategy to manage CKD needed a definition
and diagnostic criteria. The 2002 Kidney Disease Outcomes
Quality Initiative (KDOQI) staging guidelines utilizing the
Modification of Diet in Renal Disease (MDRD)-derived
estimate of glomerular filtration rate (eGFR) from serum
creatinine concentration was a much needed start. Unfortu-
nately both components have flaws, which undermine their
laudable objectives and detract from their benefits.1,2
Since its publication, the KDOQI construct has been used
as a two-dimensional grid to estimate the prevalence and
burden of CKD worldwide.3 The significance of these
estimates were difficult to assess because the definition itself
determines the prevalence, which in turn is inversely related
to the thresholds of the diagnostic criteria. In practice, what
has often been provided is the distribution of values for single
measurements of eGFR in various populations without
applying the test of chronicity. Many clinical nephrologists
found the subsequent announcements that 1:10 of the
citizens in the communities they served were suffering from
CKD implausible.
It has also been justified as a cardiovascular risk tool.
Although there is an association between kidney dysfunction
(as assessed by eGFR and/or proteinuria) and cardiovascular
risk, a causal relationship has not been proven; the effect is
largely confined to patients with overt renal failure (eG-
FRo45 ml/min per 1.73 m2) and there are as yet no
therapeutic implications. There is also a relationship of
albuminuria with cardiovascular risk, although a direct cause
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and effect relationship also remains unproven. Abnormal
albuminuria may simply be a marker of a generalized
disturbance of endothelial cell function and a risk factor for
future cardiovascular events. A risk factor is not a disease.4
The next difficulty was the use of the KDOQI-CKD
definition and staging system in clinical practice and its
application to individual patients. It proved quite blunt and
caused difficulties with the use of the word ‘disease.’
Reservations and dissatisfaction with this construct are
growing,4–11 and have most recently been clearly articulated
by Bauer et al.11 In this perspective, we rehearse the reasons
for dissatisfaction. The criticisms of the KDOQI-CKD
construct are directed both at the premises that underlie its
design and its performance in clinical practice. Herein, we
propose a modified basis for designing a staging system and
offer a working option for consideration by the nephrology
community.
OBJECTIONS TO THE PREMISES THAT UNDERLIE THE KDOQI
DEFINITION AND STAGING SYSTEM FOR CKD
1. Although described as a staging system, it is
actually a grading system based on arbitrary bands of eGFR
values.
The KDOQI-CKD system is numerical,1–5 and linear from
stages 1 to 3, implying a smooth progression from one stage
to the next three stages. Although there is a qualitative
difference between the first two and the next three, the system
relies heavily on eGFR creating overlap between stages.
This is a particular problem for stage 3 (eGFR 30–59 ml/min
per 1.73 m2), which includes the steepest part of the eGFR/
CKD relationship and will allocate the same stage to
individuals with chronic renal insufficiency as that to
individuals with inconsequential reduction in kidney func-
tion. The weakness of the staging system is that it is largely
unidimensional.
2. The system asserts that the normal GFR is 490 ml/min
per 1.73 m2 in both genders and across the adult age range in
all ethnic groups, and that an eGFR o60 ml/min per 1.7 m2
is pathological. This ignores the difference between a
reference and a normal range.
The KDOQI-CKD staging system is based on the premise
that the lower limit of normal GFR (and eGFR) in man is
90 ml/min per 1.73 m2. This relies on the data in the young
individuals reported in the 1950 paper of Davies and Shock12
using inulin clearance in just 72 hospitalized men (no
women), and the 1969 studies of Wesson.13 This conclusion
ignores biological variation, and the redundancy and reserve
in GFR with which most humans are endowed.
The staging bands of GFR are absolute and arbitrary, and
are at variance with observations of both formally mea-
sured14 and estimated GFR in the population.15
It declares an eGFR of o90 and 460 ml/min per 1.73m2
as being ‘mildly’ reduced. In fact, in population studies the
majority of individuals (younger males being the exception)
have eGFRs of o90 ml/min per 1.73 m2.14
3. The system ignores the age-related changes in GFR.
Population surveys have shown a consistent age-related
reduction in GFR and eGFR, which is apparent before old
age.14,15.The estimates from iothalamate GFR measurements
suggest a reduction beginning from the age of about 20 to 30
years, by 4.6 ml/min per decade in men and by 7.1 ml/min in
women.15 We believe that this decline in GFR with age is a
natural and not a pathological phenomenon. Indeed, there
are morphological and functional differences in the kidneys
of the elderly compared with those of the young, which are
explained in part by differences in their vasculature. As this is
a generalized phenomenon observed in all circulations and in
all elderly individuals, it is a semantic point as to whether this
represents a natural process of tissue and organ senescence or
a form of pathology.16 The consistency of the changes
supports the view that they are fundamentally related to
natural organ senescence. Of course, other diseases, such as
diabetes and hypertension, can be superimposed on the
natural aging process and influence the decline of GFR and
the prevalence of CKD. Older individuals are undoubtedly at
much higher risk of suffering from CKD.
4. The system has been linked to an imprecise estimating
measurement of GFR, the four-variable MDRD formula.
The MDRD formula was originally derived from studies
on US patients with known CKD participating in a clinical
trial. It was not validated in patients of different ages, habitus,
or ancestry; yet it is now being applied to diverse populations
without proven kidney disease whose serum creatinine
concentrations are much lower than those used in the
derivation of the formula. The laboratory method of
measuring the serum creatinine concentration is also
important, particularly its calibration to a known standard
of reference. This imprecision in determining eGFR in
patients without kidney disease has been shown to be as
much as 30% of the true GFR. Although many laboratories
warn clinicians of the tendency of the formula to under-
estimate the true GFR, the results of the calculations will be
taken at face value. If eGFR is to be central to a diagnostic
system it has to be more accurate. Given the serious
consequences of true CKD, ‘false’ diagnoses are unacceptable.
An additional issue is the applicability of the equation to
groups with ancestry and culture divergent from the
population from which the formula was derived. Studies in
groups not well represented in the original sample from
which the MDRD equation was derived have shown
significant discrepancies, leading to ‘misclassification’ of
those of the CKD stage.17 For example, in a carefully
performed population-based study from China, about two-
thirds of patients were misclassified as having stage 3 instead
of stage 2 CKD, when eGFR was compared with a reference
GFR standard. A Chinese-specific adaptation of the MDRD
formula was developed, which classified the CKD stage of
these Chinese patients much more accurately.18
5. The system defines and allows diagnosis of three stages
of CKD on eGFR alone.
Defining a disease on a laboratory measurement alone is
at odds with the traditional clinical method, which requires
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integration of a formally obtained history, a physical
examination and appropriate investigation to reach a work-
ing diagnosis, and to estimate a prognosis. The designation of
‘disease’ also infers that the identified property conveys some
material ‘disadvantage’ (survival, morbidity) to the indivi-
dual compared with other similar individuals not showing
the property. We suggest that if the level of eGFR is a sole
criterion for diagnosing CKD, any choice of an absolute
threshold value is bound to be diagnostically imprecise.
Given the redundancy in renal functional capacity in
mammals, it is reasonable and appropriate to ask what
degree of GFR reduction would be patho-physiologically
significant (for example, confering a unique disadvantage)?
We suggest that this would be a level insufficient for
maintaining homeostasis. Some of the objective evidence
for ‘insufficiency’ would be abnormal sodium balance
causing hypertension, a blunted erythropoietin axis causing
anemia, disturbed vitamin D, calcium, and phosphate
balance causing secondary hyperparathyroidism. These
derangements are very common if not universal when the
GFR is o30 ml/min per 1.73 m2, but their prevalence is
variable and unpredictable in individuals with eGFR values
above this threshold.19 At an eGFR of o30 ml/min per
1.73 m2 the serum creatinine concentration is invariably
increased above the normal range for gender even in aged
persons.
PROBLEMS ARISING FROM THE USE OF THE KDOQI-CKD
CLASSIFICATION SYSTEM WITH MDRD eGFR IN CLINICAL
PRACTICE
The normal range of GFR implicit in the KDOQI-CKD
staging system and the use of the MDRD formula to estimate
it create anomalies, which challenge its validity for classify-
ing, staging, and assessing CKD in individuals. Exceptions
prove, by which is meant test, rules.
1. Examination of the data of the National Health and
Nutrition Examination Surveys from the USA shows that
a minority of the population 460 years of age have a
‘normal’ GFR (defined as 490 ml/min per 1.73 m2) and
about 25% of individuals 470 years have eGFRso60 ml/
min per 1.73 m2 and so are automatically classified as
having CKD, irrespective of the presence or absence of
features suggesting ‘kidney damage,’ for example,
proteinuria.20
2. Patients with very different eGFR values will be classified
as having the same stage of CKD. For example, a 20-year-
old man with an eGFR of 35 ml/min per 1.73 m2,
macroproteinuria, and deteriorating renal function is
classified as having the same stage of CKD (stage 3 CKD)
as a 70-year-old woman with an eGFR of 55 ml/min per
1.73 m2 with no supporting evidence of kidney disease.
The young male has significant renal impairment with an
eGFR of B30% of that predicted for age and gender,
whereas the older woman has an eGFR close to the average
for her age. The implications for each of them are
completely different.
3. There are inconsistencies in the differences in the
prevalence rates of the stage of CKD. The prevalence rates
of stages 4 and 5 CKD (unequivocal renal failure) are
about the same (E0.2–0.4% of the US population),
whereas stage 3 CKD is 10–20 times more common at
4.2%. This suggests that stage 3 CKD is not simply a stage
in the evolution of CKD but a state that seldom progresses
to kidney failure. Indeed follow-up of patients classified as
having stage 3 CKD has shown this to be true.21 In
addition, in the KDOQ-CKD system patients are classified
as having stage 3 CKD even in the absence of proteinuria
or other features of ‘kidney damage’. It is well known that
when proteinuria is present along with moderately
depressed eGFR (30–59 ml/min per 1.73 m2), the like-
lihood of progression to later stages of CKD is greatly
enhanced.22 Similarly, it appears that it is the presence of
micro-albuminuria, and not the eGFR, which is the
marker of cardiovascular risk in patients with CKD stages
1–3.23 Another paradox is that CKD stages 3–4 are
found to be more common in women, but stage 5 CKD
(unequivocal kidney failure) is much more common
in men.
4. The unreliability of eGFR measurements 460 ml/min per
1.73 m2 has led to a policy not to give a precise value for
eGFR if it is 460 ml/min per 1.73 m2 and to report it as
such. Nephrologists have long complained that reliance on
a ‘normal’ plasma creatinine concentration has meant that
a substantial loss of kidney function of up to 50% is not
appreciated. Ignoring eGFR values of 460 ml/min per
1.73 m2 leads to making the same error. This lack of
confidence in eGFR is also admitted by the fact that it is
not recommended for use in individuals being considered
as kidney donors who have formal measurements of GFR
using isotopes or iothalamate.24
5. The unreliability of eGFR values 4 60 ml/min per 1.73 m2
removes any justification for differentiating between CKD
stages 1 and 2.
6. The majority (74% in one study) of live kidney donors
will have eGFR values of o60 ml/min per 1.73 m2
following donation of a single kidney and they will
therefore be labeled as having CKD stage 3.25
A proposed modified staging system of CKD for debate
The purpose of this and any CKD staging system should be to
inform the patient and doctor of the consequences of kidney
disease, by describing its severity, its prognosis and implica-
tions for management (Table 1). The following proposal is
based on a recognition of the differences among kidney
disease, reduced kidney function, and kidney insufficiency.
There is a need to avoid the conflation of these different
states inherent in the KDOQ-CKD construct. These propo-
sals are not novel as they have been described in principle by
Poggio and Rule.9 They may provide a structure that is more
congruent with the clinical condition of the patient and
avoids the adverse consequences of the simpler K/DOQI-
CKD system.
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‘CKD’ is a term that should be applied only to individuals
in whom there is a specific, persisting, irreversible, pathology
of the kidney(s) recognized by (i) morphological abnormal-
ities on histology or imaging and/or, (ii) persistent
abnormalities in the composition of the urine, such as
macro-albuminuria and/or hematuria or (iii) a reduction in
kidney function causing effects attributable to functional
insufficiency. So defined, CKD will also include at least a
potential for progression to ‘end stage’ chronic renal failure.
The incorporation of the word disease within the term CKD
is justified because the described abnormalities represent a
present or potential disadvantage.
‘Reduced kidney function’ in this concept of CKD would
be established by the finding of an eGFR less than fifth
percentile for healthy individuals of similar age, gender, and
ancestry.
The term chronic renal failure/insufficiency is used to
mean the state in which there is a reduction in overall kidney
function, such that there are defects in kidney-dependent
homeostasis causing clinical and metabolic consequences in
proportion to the severity of the reduction.
We believe that three principles should be embodied in
any staging system of CKD.
1. The stages should have a sequence that reflects the severity
of renal injury, the degree of functional impairment, the
risk of complications, and progression.
2. It should recognize that evidence of disease will usually be
both structural (including imaging and/or pathology) and
based on laboratory testing for signs of kidney injury
(such as macro-proteinuria and hematuria or both), and
in the later stages, functional (for example, GFR related).
The degree of reduction in function should be used for
staging and not diagnosing CKD
3. Any eGFR value used for staging should be referenced to
age and gender percentiles, based on available data (which
may ultimately be shown to differ between ancestral and
geographical groups and require special adaptations of the
eGFR-estimating formulas). At least two values separated
by 3 months or more could be retained as the arbitrary
standard for defining ‘chronicity’, but this requires further
debate.26
As described below, evidence of kidney damage should be
a sine qua non for the diagnosis of CKD, with renal function
(eGFR) function conserved in stage 1; reduced but sufficient
for health and homeostasis in stage 2; insufficient for health
in stage 3; and a threat to life in stage 4. Stage 5 would apply
to those patients receiving dialysis treatment. Whether this
staging system should be applied to renal transplant
recipients is debatable, as almost all of them will have a
single kidney with some degree of renal injury. If it were so
they could be categorized at the appropriate stage of CKD as
above, but with the modifying suffix (T).
Stage 1 CKD would be applied to the early form of
structural disease identified by histology, imaging, or inferred
from laboratory evidence of kidney damage including, for
example, persistent macro-albuminuria, but without any
associated reduction in renal function. The eGFR should be
greater than fifth percentile for the age and gender of the
patient (preferably using an ancestrally specific estimating
formula). Examples include adult polycystic kidney disease in
young adults, or many forms of glomerular, interstitial, or
vascular diseases.
Stage 2 CKD would also require evidence of overt kidney
damage, but in addition a reduction in kidney function
(eGFR less than fifth percentile for age and gender). For
Table 1 | A proposed new CKD staging system
Stagea,b Description Kidney function Diagnostic evidence Implications
1 Structural disease with normal
kidney function
eGFR greater than fifth
percentile for healthy matched
patients
Macro-albuminuria and/ or
glomerular hematuria
Abnormal histology
Abnormal imaging
Assessment for precise
diagnosis and management
2c Structural disease with reduced
kidney function and reserve, but
without clinically evident
functional insufficiency
eGFR less than fifth percentile
for healthy matched patients,
but 430 ml/min per 1.73 m2
Macro-albuminuria and/or
glomerular hematuria
Abnormal histology
Abnormal imaging
No complications of reduced
kidney function
As above, but require
monitoring of rate of change of
kidney function, and testing for
consequences of kidney
insufficiency
Awareness of lack of reserve
3c Structural disease with
insufficient kidney function for
health (chronic renal failure/
insufficiency)
15–30 ml/min per 1.73 m2 c Structural disease present or
inferred
Complications of reduced
kidney function
Active management of
complications of insufficiency
Planning for renal replacement
treatment or not
4 Severe structural disease with
life-threatening deficiency of
kidney function
o15 ml/min per 1.73 m2 Structural disease present or
inferred
Close monitoring for triggers to
start RRT or enrollment in a
conservative care program
5 Advanced/complete destruction Dialysis dependent Not applicable Specialist supervision
CKD, chronic kidney disease; eGFR, estimate of glomerular filtration rate; RRT, renal replacement treatment.
aThe suffix ‘P’ could denote ‘progression’.
bThe suffix ‘T’ could denote renal transplant recipient.
cThe distinction between stages 2 and 3 should be clinical rather than based on absolute eGFR. Patients would be tested for evidence of functional consequences of renal
insufficiency (metabolic and endocrine). If present they would be placed in stage 3 irrespective of eGFR, which may be 430 ml/min per 1.73 m2.
1012 Kidney International (2009) 75, 1009–1014
p u b l i c f o r u m CG Winearls and RJ Glassock: Dissecting and refining the staging of CKD
consistency with K/DOQI the cutoff from stage 3 could be an
eGFR of 30 ml/min per 1.73 m2. We acknowledge that this is
arbitrary. We suggest that if evidence of a clinically relevant
complication or consequence of reduced kidney function
(for example, anemia) is present, the patient should be placed
in stage 3.
Stage 3 CKD would include patients in whom the eGFR
lay between 15 and 30 ml/min per 1.73 m2. Evidence of
kidney injury would almost certainly be present, as would
complications of renal insufficiency. This higher stage takes
account of the higher risk of such patients progressing to
stage 4 CKD. This is the stage at which there will be
preparation for renal replacement treatment and the most
active management of complications.
Stage 4 CKD would only require that the eGFR be less than
15 ml/min per 1.73 m2, a GFR below which it is generally
accepted that there is a significant risk to the life and health
of the patient. (Common sense allows one to infer the
presence of structural disease and complications.) Such
patients will automatically be under the care of a nephrol-
ogist unless renal replacement treatment is not intended, in
which case responsibility for palliative care should be shared
or devolved.
Stage 5 CKD would be applied to patients receiving regular
renal replacement therapy in the form of hemodialysis or
peritoneal dialysis.
Patients with renal transplants and varying degrees of
kidney damage and/or eGFR will be categorized at the
appropriate stage of CKD as above, but with the modifying
suffix (T). Thus, a 65-year-old patient who had received a
renal transplant 5 years earlier and whose eGFR is 40 ml/min
per 1.732 and who had 2þ proteinuria would be categorized
as having stage 2 CKD (T).
Patients with an eGFR less than fifth percentile but
430 ml/min and without any evidence of structural renal
disease (that is, normal imaging, no urinary abnormalities)
and no evidence of complications should not be described as
having chronic kidney disease but as having ‘isolated reduced
kidney function of uncertain significance.’ This description
will accommodate a significant minority of the elderly
patients who have undergone unilateral nephrectomy and
those who have a non-renal cause of a reduced GFR, such as
heart failure or hepato-renal syndrome. They require regular
re-measurement of eGFR to establish whether their renal
function is stable, and they and their doctors should be aware
of the lack of renal reserve when drugs are prescribed, surgery
is performed, or intercurrent acute illnesses supervene.
It should be emphasized that we have specifically excluded
patients with isolated urinary albumin excretion rates below
that readily detected by semi-quantitative methods (‘dipstick’
positive proteinuria) but above the normal urine albumin
excretion rate, also known as microalbuminuria, or reduced
GFR (age/gender corrected) without any collateral evidence
of kidney injury from the definition of CKD. The exclusion of
isolated ‘microalbuminuria’ from the definition of CKD is
bound to be controversial. However, it is our contention that
such albuminuria is a manifestation of a systemic disturbance
affecting all microcirculations and this does not justify it
being a sufficient diagnostic criterion for chronic kidney
disease.27 Thus an obese person with a normal eGFR and
‘microalbuminuria’ would not be considered to have CKD in
this construct unless there is histological proof.28 Similarly, a
diabetic patient with a normal eGFR and ‘microalbuminuria’
would not be labeled as having CKD. Both patients would be
regarded as being at increased risk for developing CKD and
also of manifesting cardiovascular disease at a future point in
time.
FURTHER RECOMMENDATIONS
There is a clear and pressing need for a more reliable method
for the estimation of GFR in individuals with serum
creatinine concentrations in the upper part of the normal
range. Perhaps serum cystatin C level measurements will help
eventually meet this need.
Percentile charts of eGFR in healthy individuals over the
full age range and in both genders and in different
populations are needed.15 These age- and gender-specific
percentile charts should be made available in primary
care not only to allow selection of patients requiring
referral, but also to track the progress of patients diagnosed
with CKD to trigger referral when a stage requiring
specialist input is reached or an unpredicted deterioration
is observed.
All patients with stage 1 CKD should be assessed either in
person or by data review by a nephrologist, and a decision
reached as to whether specialist assessment is required for
appropriate evaluation such as renal biopsy, genetic testing,
or additional imaging studies. All patients with stage 2–4
should be under the care of, or at the very least have access to,
the advice of a nephrologist. The decision as to whether
specialist follow-up is required will be based on the likely
‘added value’ of attendance at a specialist clinic, for example,
to institute interventions that may halt the disease process,
start or modify measures designed to delay progression, or
mitigate complications. There would be merit in further
refining the staging system with a suffix such as ‘P’ to indicate
the risk of progression, the indicators of which have recently
been discussed by Taal and Brenner.29 This will free
nephrologists of the burden of monitoring stable patients.
All patients with progressive stage 3 CKD should be seen
regularly by a nephrologist, in order to determine the need
for and the timing of preparation for renal replacement
treatment. All stage 4 CKD patients will be under the care of
a nephrologist unless a co-morbidity such as advanced
malignant disease makes this inappropriate.
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